BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
As of the date of this press release, the Company has 11,594,101 common shares outstanding.MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on Wednesday, November 20, 2024 before market opening. A presentation on the Company's third quarter and year-to-date 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
安大略省密西沙加市，2024年11月13日（環球新聞通訊社） -- BioSyent Inc.（"BioSyent"，"公司"，tsx創業公司：RX）將於2024年11月20日星期三在市場開盤前發佈截至2024年9月30日的三個月和九個月的財務業績。公司總裁兼首席執行官René Goehrum將提供公司2024年第三季度和至今的業績展示，發佈當天也將在公司網站上提供。
About BioSyent Inc.
關於BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
BioSyent在tsx交易所上市，交易標的爲"RX"，是一家有盈利的增長性專業藥品公司。該公司專注於入許可證或收購已成功開發、安全有效、有證據證明可以改善病患生活的藥品和其他保健產品。BioSyent通過其社區、專業和國際業務部門將其產品推銷給醫療保健專業人員，幫助他們治療病人。
As of the date of this press release, the Company has 11,594,101 common shares outstanding.
截至本新聞稿發佈之日，公司共有11,594,101股普通股流通。
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit .
要獲取TSX Venture Exchange的直接市場報價和其他公司財務信息，請訪問。
For further information please contact:
要了解更多信息，請聯繫：
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
Rene C. Goehrum先生
董事長兼首席執行官
BioSyent公司
電子郵件：investors@biosyent.com
電話：905-206-0013
網站：
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
本新聞稿可能包含前瞻性信息或聲明。這裏的內容代表我們的判斷，截至發佈日期，並受到風險和不確定性的影響，這些風險和不確定性可能導致實際結果或結果與前瞻性信息或聲明有實質性不同。潛在的風險可能包括但不限於臨床試驗、產品開發、未來收入、運營、盈利能力和獲得監管批准。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
tsx創業公司交易所及其監管服務提供商（如tsx創業公司交易所政策中所定義的那樣）對本新聞發佈所含信息的充分性或準確性不負任何責任。
譯文內容由第三人軟體翻譯。
